Wegener granulomatosis

American Journal of the Medical Sciences

Volumn 321, Issue 1, 2001, Pages 76-82

  Langford, C A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cyclophosphamide; Granuloma; Methotrexate; Vasculitis; Wegener

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE;

ADOLESCENT; ADULT; AGED; BLOOD VESSEL OCCLUSION; CHILD; CLINICAL FEATURE; CONFERENCE PAPER; FOLLOW UP; GRANULOMATOUS VASCULITIS; HISTOPATHOLOGY; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; WEGENER GRANULOMATOSIS;

EID: 0035161888     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200101000-00011     Document Type: Conference Paper

References (38)

1. Wegener granulomatosis: An analysis of 158 patients
2. Pathogenesis of vasculitis syndromes
3. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis
4. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis
5. Wegener's granulomatesis: Prospective clinical and therapeutic experience with 85 patients for 21 years
6. Tracheobronchial involvement in Wegener's granulomatosis
7. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis)
8. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients
9. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients
10. Segmental necrotising glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?
11. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis
12. Antineutrophil cytoplasmic antibodies
13. Association between active Wegener's granulomatosis and anticytoplasmic antibodies
14. Anticytoplasmic autoantibodies: Their immunodiagnostic value in Wegener's granulomatosis
15. Antineutrophil cytoplasmic autoantibody testing in vasculitides
16. Clinical relevance of testing for antineutrophil cytoplasm antibodies (ANCA) with a standard indirect immunofluorescence ANCA test in patients with upper or lower respiratory tract symptoms
17. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis
18. The diagnostic utility of c-ANCA in Wegener's granulomatosis
19. Prevention of relapses in Wegener's granulomatosis by treatment based on anti-neutrophil cytoplasmic antibody titer
20. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis
21. The use of alkylating agents in the treatment of Wegener's granulomatosis
22. Wegener's granulomatosis: Studies in eighteen patients and a review of the literature
23. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis
24. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
25. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network
26. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis
27. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide
28. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis
29. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate
30. An analysis of forty-two Wegener's granulomatesis patients treated with methotrexate and prednisone
31. Methotrexate use in systemic vasculitis
32. Induction of remission in Wegener's granulomatosis with tow dose methotrexate
33. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice
34. A staged approach to the treatment of Wegener's granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance
35. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/ sulfamethoxazole
36. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement
37. Cyclosporin A therapy for Wegener's granulomatosis
38. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis